Ser644

Site Information
ssEELHDsPRDNsDP SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 467985

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 )
Disease tissue studied:	melanoma skin cancer ( 5 )
Relevant cell line - cell type - tissue:	32Dcl3 (myeloid) [FLT3 (mouse), transfection, chimera with human FLT3-ITD mutant (corresponding to wild type P36888 ( 4 ) , 32Dcl3 (myeloid) ( 4 ) , brain ( 3 ) , macrophage-bone marrow ( 2 ) , macrophage-bone marrow [DUSP1 (mouse), homozygous knockout] ( 2 ) , MEF (fibroblast) [TSC2 (mouse), homozygous knockout] ( 1 ) , skin [mGluR1 (mouse), transgenic, TG mutant mice] ( 5 )

Upstream Regulation
Treatments:	LPS ( 2 )

References
1	Yu Y, et al. (2011) Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science 332, 1322-6 21659605 Curated Info
2	Weintz G, et al. (2010) The phosphoproteome of toll-like receptor-activated macrophages. Mol Syst Biol 6, 371 20531401 Curated Info
3	Wiśniewski JR, et al. (2010) Brain phosphoproteome obtained by a FASP-based method reveals plasma membrane protein topology. J Proteome Res 9, 3280-9 20415495 Curated Info
4	Choudhary C, et al. (2009) Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes. Mol Cell 36, 326-39 19854140 Curated Info
5	Zanivan S, et al. (2008) Solid tumor proteome and phosphoproteome analysis by high resolution mass spectrometry. J Proteome Res 7, 5314-26 19367708 Curated Info